

12. The use of the pharmaceutical composition according to claim 11, in the manufacture of a medicament for the treatment of heart failure and peripheral arterial disease, the pharmaceutical composition further comprising one or more other additional therapeutic agents including: anti-diabetic agents, anti-hyperglycemic agents,
5 anti-hyperinsulinemic agents, anti-retinopathic agents, anti-neuropathic agents, anti-nephropathic agents, anti-atherosclerotic agents, anti-ischemic agents, anti-hypertensive agents, anti-obesity agents, anti-dyslipidemic agents, anti-hyperlipidemic agents, anti-hypertriglyceridemic agents, anti-hypercholesterolemic agents, anti-restenotic agents, anti-pancreatic agents, lipid lowering agents, anorectic
10 agents, memory enhancing agents, anti-dementia agents, cognition promoting agents, appetite suppressants, ~~treatments for heart failure, treatments for peripheral arterial disease and~~ anti-inflammatory agents.

13. The pharmaceutical composition according to claim 11, further comprising a
15 dipeptidyl peptidase-IV inhibitor and/or a sodium-glucose transporter-2 inhibitor.

14. The use of aA compound of any one of claims 1 to 10 in the manufacture of a medicament for ~~the use in~~ prevention~~ing~~, modulation~~ing~~ or treatment~~ing~~ of diabetes, hyperglycemia, impaired glucose tolerance, gestational diabetes, insulin resistance,
20 hyperinsulinemia, retinopathy, neuropathy, nephropathy, diabetic kidney disease, acute kidney injury, cardiorenal syndrome, acute coronary syndrome, delayed wound healing, atherosclerosis and its sequelae, abnormal heart function, congestive heart failure, myocardial ischemia, stroke, Metabolic Syndrome, hypertension, obesity, fatty liver disease, dislipidemia, dyslipidemia, hyperlipidemia, hypertriglyceridemia,
25 hypercholesterolemia, low high-density lipoprotein, high low-density lipoprotein, non-cardiac ischemia, pancreatitis, lipid disorders, neurodegenerative disease, cognitive impairment, dementia, liver diseases and liver cirrhosis.

15. A compound for use according to claim 14, wherein the compound of any one of
30 claims 1 to 10 is used simultaneously, separately or sequentially with an additional therapeutic agent.